Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 2543-2550

  Miller, Amanda K ^a   Hambly, David M ^a   Kerwin, Bruce A ^a   Treuheit, Michael J ^a   Gadgil, Himanshu S ^a  

^a AMGEN INC   (United States)

Author keywords

Analytical biochemistry; Biotechnology; Glycoprotein; Glycosylation; HPLC (high performance pressure liquid chromatography); Macromolecular prodrugs; Mass spectrometry; Proteins

Indexed keywords

ARGININE; GLUCOSE; IMMUNOGLOBULIN HEAVY CHAIN; LYSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAB1; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; COMPLEMENTARITY DETERMINING REGION; GLYCATION; ION EXCHANGE CHROMATOGRAPHY; MUTATION; NONHUMAN; PH; PROCESS DEVELOPMENT; PROTEIN POLYMORPHISM;

EID: 79955577669     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22504     Document Type: Article

References (27)

1. Jenkins N, Murphy L, Tyther R. 2008. Posttranslational modifications of recombinant proteins: Significance for biopharmaceuticals. Mol Biotechnol 39(2):113-118.
2. Sinha S, Pipes G, Topp EM, Bondarenko PV, Treuheit MJ, Gadgil HS. 2008. Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs. J Am Soc Mass Spectrom 19(11):1643-1654.
3. Gadgil HS, Bondarenko PV, Pipes GD, Dillon TM, Banks D, Abel J, et al. 2006. Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis. Anal Biochem 355(2):165-174.
4. Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, et al. 2007. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry 46(6):1534-1544.
5. Wakankar AA, Liu J, VanderVelde D, Wang YJ, Shire SJ, Borchardt RT. 2007. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. J Pharm Sci 96(7):1708-1718.
6. Hambly DM, Banks DB, Scavezze JL, Siska CC, Gadgil HS. 2009. Detection and quantitation of IgG 1 hinge aspartate isomerization: A rapid degradation in stressed stability studies. Anal Chem 81(17):7454-7459.
7. Gadgil HS, Pipes GD, Dillon TM, Treuheit MJ, Bondarenko PV. 2006. Improving mass accuracy of high performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry of intact antibodies. J Am Soc Mass Spectrom 17(6):867-872.
8. Zhang Z, Pan H, Chen X. 2009. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev 28(1):147-176.
9. Meert CD, Brady LJ, Guo A, Balland A.2010. Characterization of antibody charge heterogeneity resolved by preparative immobilized pH gradients. Anal Chem 82(9):3510-3518.
10. Brancia FL, Bereszczak JZ, Lapolla A, Fedele D, Baccarin L, Seraglia R, et al. 2006. Comprehensive analysis of glycated human serum albumin tryptic peptides by off-line liquid chromatography followed by MALDI analysis on a time-of-flight/curved field reflectron tandem mass spectrometer. J Mass Spectrom 41(9):1179-1185.
11. Lapolla A, Tonani R, Fedele D, Garbeglio M, Senesi A, Seraglia R, et al. 2002. Nonenzymatic glycation of IgG: An in vivo study. Horm Metab Res 34(5):260-264.
12. Lapolla A, Fedele D, Aronica R, Garbeglio, D'Alpaos M, Seraglia R, et al. 1996. The in vivo glyco-oxidation of alpha- and beta-globins investigated by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 10(9):1133-1135.
13. Bakhti M, Habibi-Rezaei M, Moosavi-Movahedi AA, Khazaei MR. 2007. Consequential alterations in haemoglobin structure upon glycation with fructose: Prevention by acetylsalicylic acid. J Biochem 141(6):827-833.
14. Yan SF, Ramasamy R, Schmidt AM. 2008. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4(5):285-293.
15. Yamagishi S, Nakamura K, Imaizumi T. 2005. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 1(1):93-106.
16. Goh SY, Cooper ME. 2008. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93(4):1143-1152.
17. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Soukourian, et al. 1994. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 91(16):7742-7746.
18. Gadgil HS, Bondarenko PV, Pipes G, Rehder D, McAuley A, Perico N, et al. 2007. The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J Pharm Sci 96(10):2607-2621.
19. Banks DD, Hambly DM, Scavezze JL, Siska CS, Stackhouse NL, Gadgil HS. 2009. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J Pharm Sci 98(12):4501-4510.
20. Hunter SJ, Boyd AC, O'Harte FPM, McKillop AM, Wiggam MI, Mooney MH, et al. 2003. Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans. Diabetes 52(2):492-498.
21. Horvat S, Jakas A. 2004. Peptide and amino acid glycation: new insights into the Maillard reaction. J Pept Sci 10(3):119-137.
22. Jakas A, Horvat S. 2003. Study of degradation pathways of Amadori compounds obtained by glycation of opioid pentapeptide and related smaller fragments: Stability, reactions, and spectroscopic properties. Biopolymers 69(4):421-431.
23. Quan C, Alcala E, Petkovska I, Matthews D, Canova-Davis E, Taticek R, et al. 2008. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: Where it is, how it got there, and how it affects charge-based behavior. Anal Biochem 373(2):179-191.
24. Zhang B, Yang Y, Yuk I, Pai R, McKay P, Eigenbrot C, et al. 2008. Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal Chem 80(7):2379-2390.
25. Fischer S, Hoernschemeyer J, Mahler HC. 2008. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm 70(1):42-50.
26. Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. 1969. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci U S A 63(1):78-85.
27. Rathore AS. 2009. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 27(9):546-553.